James Mulay Sells 5,903 Shares of CG Oncology (NASDAQ:CGON) Stock

Key Points

• Director James Mulay sold 5,903 shares of CG Oncology at an average price of $43.99, totaling approximately $259,673 on October 9.
• CG Oncology's stock recently traded down 2.7% to $43.25 with a market capitalization of $3.30 billion and a price-to-earnings ratio of -24.44.
• Several analysts have issued ratings on CG Oncology, resulting in a consensus rating of "Moderate Buy" and a target price of $58.82.

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director James Mulay sold 5,903 shares of the business's stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $43.99, for a total value of $259,672.97. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

James Mulay also recently made the following trade(s):

• On Monday, September 29th, James Mulay sold 12,755 shares of CG Oncology stock. The shares were sold at an average price of $39.19, for a total value of $499,868.45.
• On Friday, September 19th, James Mulay sold 3,574 shares of CG Oncology stock. The shares were sold at an average price of $38.99, for a total value of $139,350.26.
• On Thursday, September 18th, James Mulay sold 19,112 shares of CG Oncology stock. The shares were sold at an average price of $39.01, for a total value of $745,559.12.
• On Friday, September 5th, James Mulay sold 27,015 shares of CG Oncology stock. The stock was sold at an average price of $31.53, for a total value of $851,782.95.

CG Oncology Trading Down 2.7%

NASDAQ:CGON traded down $1.21 during midday trading on Friday, hitting $43.25. 1,158,270 shares of the stock were exchanged, compared to its average volume of 998,801. The company has a market capitalization of $3.30 billion, a price-to-earnings ratio of -24.44 and a beta of 1.31. CG Oncology, Inc. has a one year low of $14.80 and a one year high of $45.56. The business has a 50-day moving average price of $31.71 and a two-hundred day moving average price of $27.08.

CG Oncology (NASDAQ:CGON - Get Free Report) last released its earnings results on Friday, August 8th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.05). CG Oncology had a negative return on equity of 19.37% and a negative net margin of 15,945.17%. Sell-side analysts forecast that CG Oncology, Inc. will post -1.31 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CGON. Weiss Ratings reiterated a "sell (d-)" rating on shares of CG Oncology in a report on Wednesday. Royal Bank Of Canada reduced their price target on shares of CG Oncology from $68.00 to $53.00 and set an "outperform" rating on the stock in a research report on Wednesday, July 16th. JPMorgan Chase & Co. increased their price objective on shares of CG Oncology from $41.00 to $47.00 and gave the stock an "overweight" rating in a research report on Friday, September 26th. Guggenheim started coverage on shares of CG Oncology in a research report on Tuesday. They set a "buy" rating and a $90.00 price objective for the company. Finally, The Goldman Sachs Group raised shares of CG Oncology to a "strong-buy" rating and set a $40.00 target price for the company in a research report on Thursday, July 10th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $58.82.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Voya Investment Management LLC lifted its position in shares of CG Oncology by 217.6% in the 3rd quarter. Voya Investment Management LLC now owns 47,986 shares of the company's stock worth $1,933,000 after purchasing an additional 32,877 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of CG Oncology by 159.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company's stock worth $182,000 after purchasing an additional 4,288 shares during the period. E Fund Management Co. Ltd. acquired a new position in shares of CG Oncology in the 2nd quarter worth approximately $232,000. Rafferty Asset Management LLC lifted its position in shares of CG Oncology by 12.3% in the 2nd quarter. Rafferty Asset Management LLC now owns 80,228 shares of the company's stock worth $2,086,000 after purchasing an additional 8,802 shares during the period. Finally, Rosalind Advisors Inc. acquired a new position in shares of CG Oncology in the 2nd quarter worth approximately $5,017,000. Institutional investors and hedge funds own 26.56% of the company's stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.